Bani Tamraz, PharmD, PhD

Title(s)Assistant Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, DavisB.S.Chemistry
    University of California, San FranciscoPharm.D.Pharmacy
    University of California, San FranciscoGeneral Practice Residency
    University of California,, San FranciscoPh.D.Pharmaceutical Sciences and Pharmacogenomics
    Collapse Awards and Honors
    University of California, Davis1998Dow Chemical Company Chemistry Scholarship
    American Association of Pharmaceutical Scientists2002  - 2003American Foundation for Pharmaceutical Education (AFPE) Gateway Research Scholarship
    University of California, San Francisco2006  - 2007Graduate Dean's Health Science Fellowship
    CHIH Foundation2008CHIH Foundation Fellowship Award
    Amgen2010  - 2011The Amgen Research Excellence in Biopharmaceutical Sciences Fellow

    Collapse Overview 
    Collapse Overview
    My primary interest is identification of genetic determinants of drug response and translating that information into practical treatment strategies: Discovery to application. The MACS/WIHS Combined Cohort Study (MWCCS), formerly The Women’s Interagency HIV Study (WIHS) cohort, a multi-center longitudinal observational cohort, currently provides the perfect laboratory for conducting pharmacogenomics (PGx) research. I have nested several PGx studies within WIHS, providing me with the opportunity to examine how PGx factors interact with other pharmacokinetic factors to determine drug exposure and treatment outcome. In particular, my work with WIHS has enabled me to examine PGx variations associated with ethnicity which is an understudied, but high priority area of research. Besides PGx studies in HIV, I have studies in the areas of pediatric bone marrow transplant, ophthalmology and in vitro fertilization.

    In addition to discovery work, I am leading projects with an overarching vision of creating the UCSF Health-School of Pharmacy service for translating known PGx findings into clinical practice. At present, I am completing CLIA-certification of a gene panel that can provide PGx guidance for the use of 42 medications in UCSF Health. Following CLIA validation, the clinical application will be launched first with lung transplant service to pre-emptively genotype patients wait listed for transplant and use PGx to guide tacrolimus dosing post- transplant. I am leading several spin off projects related to clinical application of PGx at UCSF: a cost-effectiveness analysis of PGx in transplant and development of clinical decision support (CDS) structure for delivering the PGx-based treatment recommendations to clinicians.

    In summary, I have numerous active research projects, various collaborations and a growing clinical project that I am certain will produce meaningful results.

    Collapse Research 
    Collapse Research Activities and Funding
    Defining the impact of injection drug use on antiretroviral
    NIH R01DA047063-01Jul 1, 2018 - Jun 30, 2019
    Role: Site PI
    Role Description: Provide ongoing input on the use of WIHS data related to HIV treatment and medication usage, study design, analysis and interpretation of study findings and our in depth knowledge of the WIHS cohort data as it is related to HIV treatment and measures of medication usage and adherence.
    EpiGenomics of Ethnic and Racial Disparities in ARV Exposure and Treatment Outcomes
    NIH/NIMHD U01 AI034989Aug 25, 2017 - Dec 31, 2018
    Role: Co-Investigator
    Role Description: This study provides a comprehensive assessment of genes that may underlie ethnic and racial differences in ARV exposure and HIV treatment outcomes for two common regimens, and provide a robust framework to evaluate other regimens and outcomes (e.g., hypertension, type 2 diabetes) that feature ethnic and racial minority health disparities in both HIV+ and HIV- persons.
    Genetic risk factors for adverse drug responses and toxicities in women with HIV/AIDS
    NIH/NIGMS U01 AI034989Oct 1, 2016 - Jun 30, 2017
    Role: Co-Investigator
    Role Description: The purpose of this study is to define several adverse drug reactions and toxicities (ADR/T) in 4982 women who participated in WIHS, re-sequence 80 key candidate pharmacogenes and ADR/T genes and identify common genetic and non-genetic risk factors for ADR/T in the cohort.
    Needs assessment and value proposition for translation of pharmacogenomics into clinical practice at UCSF
    UCSF Medical Center: Chancellor's Strategic Initiative Funds Jul 1, 2016 - Jun 30, 2017
    Role: PI
    Role Description: The UCSF Health and UCSF leaders recognize precision medicine to be a priority. Pharmacogenetic (PG), an important component of precision medicine, is not commonly practiced at UCSF. For this project the objective is to develop needs assessment and value proposition for 1 or 2 therapeutic targets around the optimal translation of PG into clinical practice at UCSF; a blue–print that can be expanded in real-time to other therapeutic targets.
    GWAS analysis of atazanavir in two biomatrices from women in HIV
    Center For AIDS Research Program Supplement P30 A1027763Nov 1, 2014 - Oct 31, 2015
    Role: PI
    Role Description: Using Women’s Interagency HIV Study (WIHS) research platform to discover and validate gene polymorphisms associated with atazanavir exposure estimated by a combination of intensive pharmacokinetic and sparse hair levels.
    Personalized dosing strategies for use of fludarabine in pediatric alloHCT
    UCSF Clinical Translational Science Institute (CTSI) 5KL2TR000143-10Jul 1, 2013 - Jun 30, 2016
    Role: Co-investigator
    Role Description: The overall goal of this proposal is to develop innovative personalized dosing strategies for use of fludarabine in pediatric alloHCT to ensure safe and efficacious drug therapy in all patients. The research proposed in this application will identify and quantify both genetic and non-genetic covariates that contribute to variability in fludarabine exposure. This research will also establish the relationship between fludarabine exposure and clinical outcomes. I am involved in the pharmacogenetics of this work including sequencing DNA samples.
    Women’s Interagency HIV Study (WIHS) V
    NIH/NIAID U01 AI034989Dec 1, 1997 - Dec 31, 2019
    Role: Co-Investigator
    Role Description: The WIHS is the largest and longest-duration cohort study of HIV infection in women in the U.S. The San Francisco Bay Area WIHS (SF WIHS)’s aim feature special emphasis on vascular injury and pain, assess genetic contributions and examine the outcomes. We also continue our work in measuring long term exposure to antiretroviral drugs (ARVs) using hair samples and conducting Genome-Wide Association Studies. I am the pharmacogeneticist at SF WIHS.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Zakinova, Angela, Long-Boyle, Janel R., French, Deborah, Croci, Rhiannon, Wilson, Leslie, Phillips, Kathryn A., Kroetz, Deanna L., Shin, Jaekyu., Tamraz, Bani.A practical first step using needs assessment and a survey approach to implementing a clinical pharmacogenomics consult service. Journal of American College of Clinical Pharmacy. 2018.
    2. Hysi PG, Khawaja AP, Menni C, Tamraz B, Wareham N, Khaw KT, Foster PJ, Benet LZ, Spector TD, Hammond CJ. Ascorbic acid metabolites are involved in intraocular pressure control in the general population. Redox Biol. 2019 Jan; 20:349-353. PMID: 30391827.
      View in: PubMed
    3. Sykes C, Blake K, White N, Schauer AP, Guzman BB, Cottrell ML, Tamraz B, Kashuba ADM. Development and validation of an LC-MS/MS assay for the quantification of dolutegravir extracted from human hair. Anal Bioanal Chem. 2018 Nov; 410(29):7773-7781. PMID: 30280227.
      View in: PubMed
    4. Rubin LH, Radtke KK, Eum S, Tamraz B, Kumanan KN, Springer G, Maki PM, Anastos K, Merenstein D, Karim R, Weber KM, Gustafson D, Greenblatt RM, Bishop JR. Cognitive Burden of Common Non-antiretroviral Medications in HIV-Infected Women. J Acquir Immune Defic Syndr. 2018 Sep 01; 79(1):83-91. PMID: 29781879.
      View in: PubMed
    5. Tamraz B, Huang Y, French AL, Kassaye S, Anastos K, Nowicki MJ, Gange S, Gustafson DR, Bacchetti P, Greenblatt RM, Hysi PG, Aouizerat BE. A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. Clin Pharmacol Ther. 2018 Nov; 104(5):949-956. PMID: 29315502.
      View in: PubMed
    6. Pearce CL, Stram D, Wiensch A, Frasco MA, Kono N, Den Berg DV, Anastos K, Cohen MH, DeHovitz J, Golub ET, Tamraz B, Liu C, Mack WJ. Pharmacogenetic Associations with ADME Variants and Virologic Response to an Initial HAART Regimen in HIV-Infected Women. Int J HIV AIDS Res. 2017; 4(3):154-160. PMID: 29577081.
      View in: PubMed
    7. Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics. 2013 Jul; 23(7):355-64. PMID: 23652407; PMCID: PMC3894639.
    8. Floyd JS, Kaspera R, Marciante KD, Weiss NS, Heckbert SR, Lumley T, Wiggins KL, Tamraz B, Kwok PY, Totah RA, Psaty BM. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther. 2012 May; 91(5):896-904. PMID: 22419147.
      View in: PubMed
    9. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H, Kaspera R, Bis JC, Glazer NL, Li G, Austin TR, Taylor KD, Rotter JI, Jaquish CE, Kwok PY, Tracy RP, Psaty BM. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May; 21(5):280-8. PMID: 21386754.
      View in: PubMed
    10. Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok PY, Marciante K, Heckbert SR, Psaty BM, Totah RA. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. Pharmacogenet Genomics. 2010 Oct; 20(10):619-29. PMID: 20739906; PMCID: PMC2993694.
    11. Trivedi NN, Tamraz B, Chu C, Kwok PY, Caughey GH. Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. J Allergy Clin Immunol. 2009 Nov; 124(5):1099-105.e1-4. PMID: 19748655; PMCID: PMC2783561.
    12. Reich D, Patterson N, Ramesh V, De Jager PL, McDonald GJ, Tandon A, Choy E, Hu D, Tamraz B, Pawlikowska L, Wassel-Fyr C, Huntsman S, Waliszewska A, Rossin E, Li R, Garcia M, Reiner A, Ferrell R, Cummings S, Kwok PY, Harris T, Zmuda JM, Ziv E. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet. 2007 Apr; 80(4):716-26. PMID: 17357077; PMCID: PMC1852718.